734 research outputs found
PRIVATE LABELING OF MILK AND THE IMPACT ON MARKET STRUCTURE
Industrial Organization,
Joel L. Alvis, M.D., Memphis, Tennessee, To Mr. Rivers E. Adams, (Claremont) Clarksdale, Mississippi. August 25, 1955.
https://egrove.olemiss.edu/adams_lett/1236/thumbnail.jp
How expensive is treating patients in a center of excellence for rheumatoid arthritis in Colombia?
We aimed to estimate the cost of treating patients with rheumatoid arthritis (RA) in a Center of Excellence (CoE) for rheumatic diseases located in Bogotá, Colombia. We performed a cost analysis from the standard cost estimation of a CoE program for RA care. We estimated costs of consultations, laboratory and imaging tests, and pharmacological treatment from the measurement of the health care resource utilization of the CoE standard protocol according to the activity level of the disease (DAS28). Costing process was done following the recommendation of the Colombian Institute of Health Technology Assessment (IETS, in Spanish). Mean, minimum and maximum costs were reported annually for a type case depending on severity and classified as Remission, low disease activity (LDA), moderate disease activity (MDA) and severe disease activity -SDA- (with and without bDMARD). All costs were reported in American dollars, using the average exchange rate from January to December of 2018, reported by Banco de la República de Colombia: US2,951.3 Colombian pesos. Mean total direct medical cost to treat a patient in remission is US835.5 (2,187.1). There is a considerable increase in direct medical costs from a patient in SDA and SDA+Biologics: US2,301.1-8,032.4 (8,400.3). The largest share of the cost was related to drugs, representing 39.9% for Remission, 53.6% for LDA, 75.2 for MDA, and in SDA and SDA+Biologics the proportion of what is spent on drugs for RA treatment is 88.5% and 96.7%, respectively. As the severity of the disease increases, the expenditure rate on drugs rises over the total of each activity level. With the introduction of the biological therapy, the treatment of RA is expensive, however, the CoE is an efficient way of care for RA
Characteristics and monetary compensation of caregivers for patients with rheumatic conditions
Musculoskeletal disorders (MD) are highly prevalent conditions that affect quality of life. MD cause physical and psychological dependence. Usually, the care of a patient with MD is assumed by a caregiver. The aim of this study was to describe the sociodemographic characteristics and the monetary remuneration associated to the care of a patient with MD. A cross sectional study was carried out in order to estimate the monetary remuneration related to the health care of patients with MD. A survey was applied to caregivers of patients with MD. Demographic data was collected. We asked about the relationship with the patient, the time as a caregiver and all data related to the monetary compensation. Descriptive epidemiology was done. We reported monetary data in American Dollars (USD) using the average exchange rate for 2018. We surveyed 132 caregivers. Mean age was 52 years [standard deviation 19], 72% were women, 78% were taking care of a patient with rheumatoid arthritis, 12% osteoarthrosis 2% lupus, and 2% osteoporosis. The remaining 6% were caregivers of patients with ankylosing spondylitis, fibromyalgia and Sjogren syndrome. Regarding the time as a caregiver, 48% had less than a year, 16% between two and three years, 18% more than three years, 13% more than four years, and 5% were temporarily caregivers. In our study, 85% of caregivers were a family member, while 15% a nurse or a non-related person. Regarding the compensation, 97% did not receive any salary or payment for being caregiver, the remaining 3% received between 265 and 530 USD per month. Our study demonstrated that the care for patients with MD is mainly assumed by family members. Our results agree with other studies in chronic conditions where only a small proportion of caregivers is paid. Caregivers should be considered for the health system
Quality of life and the relationship with family income in patients with rheumatoid arthritis
Objectives: To evaluate the quality of life (QoL) of patients with rheumatoid arthritis (RA) using the Quality of life in Rheumatoid Arthritis (RAQol) questionnaire. Also, to explore its relationship with income in patients attended at a specialized RA center in Bogotá, Colombia, 2018. Methods: We performed a descriptive study. The RAQol version in Spanish was applied to RA patients. The scale of the RAQol has a score from 1-10, where 10 is associated with better QoL. We excluded patients with psychological or psychiatric disorders. We asked about the monthly family income according to the Colombian minimum wage. Descriptive epidemiology was performed for each variable. A comparison of means regarding age and RAQol score was carried out. Therefore, we performed a bivariate analysis in order to explore the relationship between income and QoL, reporting Odds Ratios (OR) and confidence intervals 95% (CI95%). Results related to family income were reported in US265, 47% between US530, 9% between US795 and 3% more than US531 per/month had a higher average score in the RAQoL scale (7.1, SD5.5). The relationship of having a score lower than 6 in the RAQoL and a monthly income lower than US$530 showed an OR of 2.48 IC95% (0.99-6.22) (P=0.03). Conclusions: Our study showed that patient with a low income reports a lower QoL. Further research is needed to evaluate the alternatives that can improve QoL in patients with RA
Costs and disease activity in patients with rheumatoid arthritis treated with biologic dmards: findings in a real-life setting
Objectives: Biological DMARDs have demonstrated to modify the natural course of the disease through the inhibition of specific molecules of the immune and inflammatory responses. The objective of our study is to describe the use of biological therapy, disease activity and costs related to the treatment of patients with RA in a real-life setting in Colombia. Methods: Patients were analyzed retrospectively for 36 months and followed-up under T2T standards with a multidisciplinary approach. DAS28 was used as main clinical outcome. We included patients with severe or moderate disease activity using biological therapy. We described the percentage of patients who reached low disease activity or remission. Most expensive biological therapies were described and costed. Costs were reported in US dollars at the official rate of exchange for December 2018. Statistical analyses were done in Microsoft Excel. Results: We followed-up 1054 patients during three years, 85% were female, mean age was 57 years (SD 7.7). At the beginning of the follow-up, 52% of patients were in MDA and 48% in SDA. The most used treatment regime was certolizumab (24.57%) followed by etanercept (16.51%) and abatacept (12.81%). At the end of the follow-up, 92% patients achieved remission. Regarding costs, the most expensive therapy per/ year was etanercept (USD 11,535.00) and (adalimumab). When we calculated the average cost for all biological therapy and then compared to the number of patients who achieved remission, the costs during three years to achieve remission was $27,738,839.54 USD. Conclusions: Our study showed that biological therapy is effective when is used under a T2T strategy and with a multidisciplinary approach. However, it is an expensive option that might be used in adherent patients and candidates who met the profile for prescribing this type of pharmacological therapy, especially in developing countries where the health budgets are limited
Molecular testing dynamics is reactive to COVID-19 incidence: Observations from the colombian experience
There was a positive correlation between molecular tests conducted and COVID-19 incidence and death rate (r = 0.79, p < 0.01 and r = 0.64, p < 0.01, respectively). The cointegration (ADF) test revealed a statistically significant and closely time-dependent stochastic structure between daily COVID-19 cases and number of molecular tests (ADF, -3.50; p < 0.01)
Recommended from our members
Mechanical considerations and design skills.
The purpose of the report is to provide experienced-based insights into design processes that will benefit designers beginning their employment at Sandia National Laboratories or those assuming new design responsibilities. The main purpose of this document is to provide engineers with the practical aspects of system design. The material discussed here may not be new to some readers, but some of it was to me. Transforming an idea to a design to solve a problem is a skill, and skills are similar to history lessons. We gain these skills from experience, and many of us have not been fortunate enough to grow in an environment that provided the skills that we now need. I was fortunate to grow up on a farm where we had to learn how to maintain and operate several different kinds of engines and machines. If you are like me, my formal experience is partially based upon the two universities from which I graduated, where few practical applications of the technologies were taught. What was taught was mainly theoretical, and few instructors had practical experience to offer the students. I understand this, as students have their hands full just to learn the theoretical. The practical part was mainly left up to 'on the job experience'. However, I believe it is better to learn the practical applications early and apply them quickly 'on the job'. System design engineers need to know several technical things, both in and out of their field of expertise. An engineer is not expected to know everything, but he should know when to ask an expert for assistance. This 'expert' can be in any field, whether it is in analyses, drafting, machining, material properties, testing, etc. The best expert is a person who has practical experience in the area of needed information, and consulting with that individual can be the best and quickest way for one to learn. If the information provided here can improve your design skills and save one design from having a problem, save cost of development, or reduce difficulty in manufacturing, then my writing effort will have been worthwhile. It is also my hope that you will freely provide others with design information that you have found beneficial to the less-experienced engineers. The result will be that as a whole, the designs will improve, and the development time will be shortened from start of the design to full system operation or deployment
Health care resource utilization in patients with spondyloarthritis: A single setting analysis in Colombia
The aim of this study was to estimate the health care resource utilization in patients with spondylitis from a rheumatology care center located in Bogotá, D.C. Colombi
- …